Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan in metastatic solid tumors
2024-513611-28-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), endometrial cancer (EC) and 1 more (4 cohorts), sponsored by Gilead Sciences. Primary endpoint: Objective response rate. Planned start Jul 2022; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)endometrial cancer (EC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-513611-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513611-28-00.